WinstonWınston
Praxsyn Corporation logo

Praxsyn Corporation

PXYN
36
Medical - Pharmaceuticals · Healthcare
Price
$0.00
+0.00 (+0.00%)
Market Cap
$6,347
Winston Score
36
Winston is serious
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+939.7% over 6y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 71.1M (2012) → 739.4M (2018)

Praxsyn Corporation is a small pharmaceutical company focused on developing and sourcing hard-to-find medications. The company has worked on obtaining active pharmaceutical ingredients, including efforts around controlled substances and specialty drugs that are difficult to manufacture or source. Its potential customers include hospitals, pharmacies, and healthcare providers that need access to medications in short supply.

Praxsyn generates revenue through the sale of pharmaceutical products and ingredients, though its sales remain very limited at this stage. The company operates primarily in the United States and carries a very small market cap, meaning it is considered a micro-cap or development-stage business. Its operating margin is deeply negative, which signals the company is spending far more than it earns — a common but serious risk for early-stage pharmaceutical firms. The key risk here is whether Praxsyn can secure regulatory approvals, build reliable supply chains, and grow revenue fast enough before it runs out of capital.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

YoY Growth Rate

EPS data limited

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

18.0%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$289,636 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Praxsyn Corporation has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
58.3%
Premium pricing power — 58.3% gross margin
Operating Margin
-279.1%
Losing money on operations — -279.1%
ROCE
-2.7%
Weak — -2.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-69.0%
Shrinking sales (-69.0% YoY)
EPS YoY
-65.9%
Earnings shrinking (-65.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
-403%
Weak — only -403% of profit becomes cash
FCF Margin
-54.2%
Burning cash (-54.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.91
Moderate — manageable debt (0.91)
Interest Cover
22.59x
Comfortably covers interest (22.6x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
0.0x
Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial